Schizophrenia, psychotropic medication, and cataract

Ophthalmology

Volumn 106, Issue 4, 1999, Pages 683-687

  McCarty, Cathy A ^a   Wood, Carolyn A ^a   Fu, Cara L ^a   Livingston, Patricia M ^a   Mackersey, Sue ^a   Stanislavsky, Yury ^a   Taylor, Hugh R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; CATARACT; CATARACTOGENESIS; DISEASE CLASSIFICATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PHOTOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; SLIT LAMP;

EID: 0033504831     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)90151-3     Document Type: Article

References (20)

1. Isaac NE, Walker AM, Jick H, Gorman M. Exposure to phenothiazine drugs and risk of cataract. Arch Ophthalmol 1991;109:256-60.
2. Collman GW, Shore DL, Shy CM, et al. Sunlight and other risk factors for cataracts: an epidemiologic study. Am J Public Health 1988;78:1459-62.
3. Epidemiology of cataract [Editorial]. Lancet 1982;1392-3.
4. Roberts JE, Reme CE, Dillon J, Terman M. Exposure to bright light and the concurrent use of photosensitizing drugs. N Engl J Med 1992;326:1500-1.
5. Taylor HR, West SK, Rosenthal FS, et al. Effect of ultraviolet radiation on cataract formation. N Engl J Med 1988;319: 1429-33.
6. McCarty CA, Taylor HR. Recent developments in vision research: light damage in cataract. Invest Ophthalmol Vis Sci 1996;37:1720-3.
7. West SK. Daylight, diet, and age-related cataract. Optom Vis Sci 1993;70:869-72.
8. Thaler JS, Curinga R, Kiracofe G. Relation of graded ocular anterior chamber pigmentation to phenothiazine intake in schizophrenics - quantification procedures. Am J Optom Physiol Opt 1985;62:600-4.
9. Forrest FM, Snow HL, Erickson F, et al. Incidence of late "melanosis" side effects in chronic mental patients after long term phenothiazine therapy. Proc West Pharmacol Soc 1966;9:18-20.
10. Barsa JA, Newton JC, Saunders JC. Lenticular and corneal opacities during phenothiazine therapy. JAMA 1965;193(1):10-2.
11. Newgreen DB. Drug information profiles. Health Department Victoria, 1986.
12. Livingston PM, Carson CA, Stanislavsky YL, et al. Methods for a population-based study of eye disease: the Melbourne Visual Impairment Project. Ophthalmic Epidemiol 1994;1:139-48.
13. Taylor HR, West SK. A simple system for the clinical grading of lens opacities. Lens Research 1988;5:175-81.
14. Taylor HR, West SK. The clinical grading of lens opacities. Aust N Z J Ophthalmol 1989;17:81-6.
15. West SK, Rosenthal F, Newland HS, Taylor HR. Use of photographic techniques to grade nuclear cataracts. Invest Ophthalmol Vis Sci 1988;29:73-7.
16. Livingston PM, Lee SE, McCarty CA, Taylor HR. A comparison of participants with non-participants in a population-based epidemiologic study: the Melbourne Visual Impairment Project. Ophthalmic Epidemiol 1997;4: 73-81.
17. Swann PG, Elliott JF. Toxic cataract. Aust J Optom 1983;66: 3-12.
18. Forrest FM, Snow HL. Prognosis of eye complications caused by phenothiazines. Dis Nerv Syst 1968;29(Suppl):26-8.
19. Bond WAS, Yee GC. Ocular and cutaneous effects of chronic phenothiazine therapy. Am J Hosp Pharm 1980;37: 74-8.
20. Smith D, Pantelis C, McGrath J, et al. Ocular abnormalities in chronic schizophrenia: clinical implications. Aust N Z J Psychiatry 1997;31:252-6.